SANOVO #ESMO26: osi ± savolitinib, 1L EGFRm MET-overexpressed NSCLC (China)
➡️ mPFS IHC3+ 24.8 vs 11.1 mo, HR 0.45
➡️ mPFS ITT 24.9 vs 13.8 mo, HR 0.56
➡️ mOS 44.5 vs 34.9 mo, HR 0.48
➡️ 3-yr OS 67.4 vs 47.4%
Test MET IHC at EGFRm diagnosis?

@LungCancerRx @OncoAlert @oncodaily